ORIGINAL ARTICLE: High Expression of <scp>l</scp>‐Selectin Ligand in Secretory Endometrium is Associated with Better Endometrial Receptivity and Facilitates Embryo Implantation in Human Being

Wang, Bo; Sheng, Jian‐Zhong; He, Rong-Huan; Qian, Yuping; Jin, Fan; Huang, He‐Feng

doi:10.1111/j.1600-0897.2008.00604.x

Cited by 39 publications

(31 citation statements)

References 29 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Up to half of all unsuccessful IVF cycles may be due to implantation failure (de los Santos et al, 2003) with diminished embryo quality taking on greater importance in older women. With the availability of specific mono-and polyclonal antibodies to potential biomarkers, immunohistochemistry has supplanted histologic dating alone and remains an active area of research on endometrial receptivity (Lessey et al, 1994a,b;Kliman et al, 2006;Wang et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

Endometrial receptivity defects during IVF cycles with and without letrozole

et al. 2012

View full text Add to dashboard Cite

background: Our aim was to study ways to improve IVF success rates in women with suspected endometrial receptivity defects. methods: We conducted a retrospective cohort study examining the effect of letrozole (aromatase inhibitor) on integrin expression as a marker of endometrial receptivity. We compared IVF outcomes in 97 infertile women who had undergone anb3 integrin assessment by immunohistochemistry in mid-luteal endometrial biopsies. Of 79 women undergoing standard IVF, 29 (36.7%) lacked normal integrin expression. Eighteen other women with low integrin were studied after receiving letrozole during early IVF stimulation. An independent set of anb3 integrin-negative patients (n ¼ 15) who had undergone repeat endometrial biopsy for integrin testing while taking letrozole were re-evaluated.results: Clinical pregnancy and delivery rates were higher in women with normal anb3 integrin expression compared with those who were integrin negative [20/50 (40%) versus 4/29 (13.8%); P ¼ 0.02 and 19/50 (38%) versus 2/29 (7%); P , 0.01, respectively]. In 18 women who received letrozole early in IVF, 11 conceived (61.1%; P , 0.001) compared with integrin-negative patients who did not receive letrozole. In integrin-negative women who were rebiopsied on letrozole, 66.7% reverted to normal integrin expression. Positive endometrial aromatase immunostaining using a polyclonal antibody was a common finding in infertile patients compared with controls.conclusions: Lack of endometrial anb3 integrin expression is associated with a poor prognosis for IVF that might be improved with letrozole co-treatment. Prospective studies are needed to confirm and extend these findings but the data suggest that aromatase expression may contribute to implantation failure in some women.

show abstract

Section: Discussionmentioning

confidence: 99%

Endometrial receptivity defects during IVF cycles with and without letrozole

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Whereas L-selectin is expressed in the blastocyst (Genbacev et al 2003), the endometrial epithelial cells express its ligand (Wang et al 2008).…”

Section: Transcriptomics Of Endometrial Receptivitymentioning

confidence: 99%

Human Endometrial Transcriptomics: Implications for Embryonic Implantation

Gómez

Ruiz-Alonso

Miravet

et al. 2015

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

Human endometrium has been extensively investigated in the search for markers capable of predicting its receptive status. The completion of the Human Genome Project has triggered a rapid development of new fields in molecular biology, the "transcriptomics" being a major turning point in the knowledge acquisition of endometrial receptivity. Based on this, a customized Endometrial Receptivity Array (ERA) has been developed, which is capable of identifying the genomic signature of receptivity. This diagnostic tool showed that the window of implantation (WOI) is displaced in one out of four patients with implantation failure, allowing the identification of their personalized WOI. This strategy allows performing a personalized embryo transfer ( pET) on the day in which the endometrium is receptive. The combination of a systems biology approach and next-generation sequencing will overcome the limitations of microarrays, and will, in the future, allow elucidation of the mechanisms involved in embryo implantation.T he endometrium, which lines the inside of the uterine cavity, undergoes cyclic changes that are regulated by ovarian steroids. It can be subdivided into the basal layer that is responsible for its regenerative capacity, and the functional layer that undergoes proliferation, secretion, and tissue degeneration every month from menarche to menopause. Its aim is to prepare the optimal moment for embryonic implantation known as the window of implantation (WOI).The endometrial cycle comprises the menstrual, proliferative, and secretory phases. The proliferative phase, which corresponds to the ovarian follicular phase and increased production of estrogens, lasts until ovulation occurs. During this stage, the increasing estrogen levels cause the proliferation of the stromal cells as well as the elongation of the spiral arteries. After ovulation, with the appearance of progesterone secreted by the granulosa-luteal cells, the secretory phase begins. If implantation does not occur, the secretory phase ends, and the corpus luteum degenerates. Menstruation occurs owing to the drop of estrogen and progesterone, which resets the endometrium until pregnancy

show abstract

“…In humans, SELL ligand appears to play a key role in blastocyst attachment (Wang et al, 2008) while low levels of uterine expression are associated with implantation failure and infertility (Foulk et al, 2007;Margarit et al, 2009).…”

Section: Accepted Manuscriptmentioning

confidence: 99%